

The Expert Committee on Specifications for Pharmaceutical Preparations works towards clear, independent and practical standards and guidelines for the quality assurance of medicines. Standards are developed by the Committee through worldwide consultation and an international consensus-building process.

The following new standards and guidelines were adopted and recommended for use: the current list of available International Chemical Reference Substances and International Infrared Reference Spectra; guidelines on the active pharmaceutical ingredient master file procedure; the procedure for assessing the acceptability of male latex condoms and that of intrauterine devices for purchase by United Nations and other agencies; and a review of International Nonproprietary Names for biological and biotechnological substances.

ISBN 9789241209489



9 789241 209489

SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS

WHO Technical Report Series — 948

WHO EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS

Forty-second report

World Health
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications. The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences. To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective — the attainment by all people of the highest possible level of health.

The WHO Technical Report Series makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. An annual subscription to this series, comprising about six such reports, costs CHF 168.00/US\$ 151.00 (CHF 128.40/US\$ 115.00 in developing countries). For further information, please contact: WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int; order on line: <http://www.who.int/bookorders>).

SELECTED WHO PUBLICATIONS OF RELATED INTEREST

The International Pharmacopoeia, fourth edition.

Volume 1: general notices; monographs for pharmaceutical substances (A–O)

Volume 2: monographs for pharmaceutical substances (P–Z); monographs for dosage forms and radiopharmaceutical preparations; methods of analysis; reagents.

2006 (1500 pages), also available in CD-ROM format and on line

First supplement: general notices; monographs for pharmaceutical substances; monographs for dosage forms; general and specific monographs; methods of analysis; International Chemical Reference Substances; International Infrared Reference Spectra; reagents, test solutions and volumetric solutions, 2008 (in press)

Basic tests for drugs: pharmaceutical substances, medicinal plant materials and dosage forms

1998 (94 pages)

Basic tests for pharmaceutical dosage forms

1991 (134 pages)

Quality Assurance of Pharmaceuticals: a compendium of guidelines and related materials

Volume 1: 1997 (244 pages)

Volume 2: Good manufacturing practices and inspection.

2nd updated edition, 2007 (in press)

Also available on: WHO training modules on GMP. A resource and study pack for trainers, 2007 (CD-ROM)

WHO Expert Committee on Specifications for Pharmaceutical Preparations

Forty-first report.

WHO Technical Report Series, No. 943, 2007 (156 pages)

International Nonproprietary Names (INN) for pharmaceutical substances

Cumulative List no. 12

2007 (available in CD-ROM format only)

The use of essential medicines

Report of the WHO Expert Committee (including the 15th Model List of Essential Medicines).

WHO Technical Report Series, No. 946, 2007 (163 pages). First WHO Model List of Essential Medicines for Children (<http://www.who.int/childmedicines/en/index.html>)

WHO Expert Committee on Biological Standardization

Fifty-fifth report.

WHO Technical Report Series, No. 941, 2008 (290 pages) (in press)

Further information on these and other WHO publications can be obtained from WHO Press, World Health Organization, 1211 Geneva 27, Switzerland.

This report contains the collective views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization

WHO Technical Report Series

948

WHO EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS

Forty-second report



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data

Forty-second report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations.

(WHO Technical Report Series, No. 948)

1. Pharmaceutical preparations - standards. 2. Technology, Pharmaceuticals - standards.
3. Drug industry - legislation. 4. Quality control. I. World Health Organization.
II. Series.

ISBN 978 92 4 120948 9
ISSN 0512-3054

(NLM classification: QV 771)

© World Health Organization 2008

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications — whether for sale or for noncommercial distribution — should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.

**Typeset in Switzerland
Printed in Switzerland**

Contents

1. Introduction	1
2. General policy	8
2.1 Collaboration with international organizations and agencies	8
2.2 Cross-cutting pharmaceuticals — quality assurance issues	13
2.3 Essential medicines for children	17
2.4 Counterfeit medicines	18
3. Quality control — specifications and tests	18
3.1 <i>The International Pharmacopoeia</i> (4th edition)	18
3.2 Proposed new work plan	18
3.3 Specifications for medicines, including children's medicines	19
3.4 Revision of texts	21
3.5 General monographs for dosage forms and associated method texts	21
3.6 Radiopharmaceuticals	25
3.7 Dissolution tests for addition to specific monographs	26
4. Quality control — International Chemical Reference Substances and International Infrared Reference Spectra	28
4.1 Annual report of the WHO Collaborating Centre	28
4.2 Adoption of new International Chemical Reference Substances	28
4.3 Infrared Reference Spectra	28
5. Quality control — national laboratories	29
5.1 External Quality Assurance Assessment Scheme	29
6. Quality assurance — good manufacturing practices	30
6.1 Good manufacturing practices for active pharmaceutical ingredients	30
6.2 Good manufacturing practices for biologicals	31
6.3 Good manufacturing practices — new texts	32
7. Quality assurance — new approaches and risk analysis	32
7.1 Technology transfer	33
8. Quality assurance — distribution and trade of pharmaceuticals	33
8.1 WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce	33
9. Quality assurance — stability	37
10. Prequalification of priority essential medicines and devices	38
10.1 Procedure for prequalification of medicines	38
10.2 Procedures for prequalification of intrauterine devices and condoms	39

11. Prequalification of active pharmaceutical ingredients	39
11.1 Procedure for prequalification of active pharmaceutical ingredients	39
12. Prequalification of quality control laboratories	40
13. Active pharmaceutical ingredient master file	41
14. Regulatory guidance	42
14.1 Specific guidance on children's medicines	42
14.2 Guidelines for pharmaceutical development of generics	42
14.3 Quality of herbal and complementary medicines	43
14.4 Near infrared spectroscopy	43
15. Nomenclature, terminology and databases	44
15.1 WHO terminology used in quality assurance	44
15.2 International Nonproprietary Names for pharmaceutical substances	44
15.3 Pharmacopoeial references	44
16. Miscellaneous	45
16.1 Diethylene glycol	45
16.2 Regulatory burden — inspections	45
17. Summary and recommendations	46
Acknowledgements	53
Annex 1	
List of available International Chemical Reference Substances and International Infrared Reference Spectra	59
Annex 2	
Procedure for assessing the acceptability, in principle, of male latex condoms for purchase by United Nations agencies	71
Annex 3	
Procedure for assessing the acceptability, in principle, of TCu380A intrauterine devices for purchase by United Nations agencies	87
Annex 4	
Guidelines on active pharmaceutical ingredient master file procedure	103
Annex 5	
International Nonproprietary Names for biological and biotechnological substances: a review	113

WHO Expert Committee on Specifications for Pharmaceutical Preparations

Geneva, 15–19 October 2007

Members

Dr E. Bin Jakka Al Mansoori, Director, Drug Control Department, Ministry of Health, Abu Dhabi, United Arab Emirates

Dr H. Beltramini, San Nicolás, Argentina

Professor T.G. Dekker, Scientific Support, Research Institute for Industrial Pharmacy, North-West University, Potchefstroom, South Africa

Professor J. Hoogmartens, Laboratorium voor Farmaceutische Chemie en Analyse van Geneesmiddelen, Leuven, Belgium (*Chairperson*)

Professor Jin Shaohong, Executive Deputy Director, National Institute for the Control of Pharmaceutical and Biological Products, Ministry of Public Health, Beijing, People's Republic of China

Dr J.A. Molzon, Associate Director for International Programs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA (*Co-Rapporteur*)

Professor T.L. Paál, Director-General, National Institute of Pharmacy, Budapest, Hungary (*Co-Chairperson*)

Ms Metta Treebamroong, Senior Pharmacist, Drug Quality and Safety, Bureau of Drug and Narcotics, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand

Mr Eshetu Wondemagegnehu, Addis Ababa, Ethiopia (*Co-Rapporteur*)

Temporary advisers

Dr E. Ehrin, Director, Centrallaboratoriet, ACL, Apoteket AB, Kungens Kurva, Sweden

Professor H.G. Kristensen, Department of Pharmaceutics, Danish University of Pharmaceutical Sciences, Copenhagen, Denmark

Dr J.-L. Robert, Service du Contrôle des Médicaments, Laboratoire National de Santé, Luxembourg

Dr S. Singh, Professor and Head, Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, SAS Nagar, India

Special advisers (prequalification)

Mr P. Hargreaves, Inspection and Standards Division, Medicines and Healthcare Products Regulatory Agency, London, England

Mr D. Mubangizi, National Drug Authority, Kampala, Uganda

Dr J. Pogány, Budapest, Hungary

Representation from United Nations Offices¹

Representation from specialized agencies and related organizations²

The Global Fund to Fight AIDS, Tuberculosis and Malaria

Ms Joelle Daviaud, Technical Officer, Pharmaceutical Quality Assurance, the
Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland

Representation from intergovernmental organizations³

*Council of Europe/European Directorate for the Quality of Medicines
and HealthCare (EDQM)*

Dr John H. McB. Miller, Head, Laboratory Department, European Directorate for the
Quality of Medicines and HealthCare, Strasbourg, France

European Medicines Agency (EMA)

Dr Riccardo Luigetti, Scientific Administrator, Inspections Sector, European
Medicines Agency, London, England

Representation from nongovernmental organizations⁴

Commonwealth Pharmaceutical Association (CPA)

Ms Miranda Viljoen, Director, Pharma Technical Affairs, South African Association
of Pharmacists in Industry, Pharmaceutical Association of South Africa,
Johannesburg, South Africa

European Chemical Industry Council (CEFIC)/APIC

Dr Boris Pimentel, Global Regulatory Affairs Manager, DSM — Nutritional Products,
Basel, Switzerland

*International Federation of Pharmaceutical Manufacturers and Associations
(IFPMA)*

Dr Michael G. Beatrice, Vice President, Corporate Regulatory and Quality Science,
Abbott Laboratories, Abbott Park, IL, USA

European Federation of Pharmaceutical Industries and Associations (EFPIA)

Dr Matthias Hoepfner, Bayer HealthCare AG

Dr Fraser Stodart, Pfizer Ltd

International Pharmaceutical Excipients Council (IPEC)

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report>